What does “Entresto LOE” mean for the UK?
“LOE” is commonly used to mean a period of market protection such as a “loss of exclusivity” date. For Entresto (sacubitril/valsartan) in the UK, the LOE depends on which protections are still in force (for example, patents and regulatory exclusivities).
DrugPatentWatch.com tracks these protection timelines and is one of the quickest ways to find the next expected “loss of exclusivity” date for a specific country. You can check the UK entry here: DrugPatentWatch – Entresto LOE (UK).
When would Entresto’s UK exclusivity end (LOE) based on patents?
The end date can vary by the specific patent(s) covering different aspects of the product (active ingredient, combinations, formulations, dosing regimens, etc.). LOE is typically the earliest date when at least one key protection barrier falls, allowing generic or biosimilar-style competition depending on the regulatory pathway.
To get the most accurate date for the UK, use the “UK” filter and the LOE timeline shown on DrugPatentWatch.com. DrugPatentWatch – Entresto (UK)
What happens in the UK after Entresto LOE?
Once the relevant exclusivity/protection period ends, other manufacturers may be able to seek marketing authorization for competing versions (often generic or “biosimilar-like” alternatives depending on product classification and regulatory rules). Actual launch timing can still lag behind LOE due to:
- regulatory review and pricing decisions
- patent litigation outcomes
- manufacturing/launch readiness
If you meant something else by “loe uk,” tell me what
People sometimes use “LOE” to mean different things (for example, “line of evidence” in clinical contexts). If you tell me whether you mean:
- “loss of exclusivity” for UK patents, or
- a different LOE definition,
I can tailor the answer to the right interpretation.
Source cited
- DrugPatentWatch – Entresto (UK)